Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Immunity and Vaccines

Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

Nina Ekström, Heidi Åhman, Jouko Verho, Jukka Jokinen, Merja Väkeväinen, Terhi Kilpi, Helena Käyhty, ; the Finnish Otitis Media Study Group
Nina Ekström
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nina.ekstrom@ktl.fi
Heidi Åhman
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jouko Verho
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jukka Jokinen
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merja Väkeväinen
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terhi Kilpi
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Käyhty
National Public Health Institute (KTL), Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
National Public Health Institute (KTL), Helsinki, Finland
DOI: 10.1128/IAI.73.1.369-377.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    GMC against each of the serotypes of a 7-valent pneumococcal conjugate vaccine at different time points in infants immunized at 2, 4, 6, and 12 months of age with PncCRM (n = 54 to 56), PncOMPC (n = 44 to 55), or a control vaccine (n = 53 or 54).

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Reverse cumulative distribution curves demonstrating the percentages of children achieving various serum IgG antibody concentrations against each of the vaccine serotypes at various ages. The children were immunized at 2, 4, 6, and 12 months of age with a pneumococcal conjugate vaccine, PncCRM (n = 54 to 56) or PncOMPC (n = 44 to 55).

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Percentages and 95% confidence intervals of infants with an antibody concentrations of ≥0.35 μg/ml at 7, 12, 13, and 24 months of age. The infants were immunized at 2, 4, 6, and 12 months of age with a 7-valent pneumococcal conjugate vaccine, PncCRM (n = 54 to 56) or PncOMPC (n = 44 to 55), or a control vaccine (n = 53 or 54).

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    MAIs and 95% confidence intervals of anti-pneumococcal type 6B, 19F, and 23F capsular polysaccharide IgG antibodies in infants immunized at 2, 4, 6, and 12 months of age with 7-valent pneumococcal conjugate vaccine, PncCRM (n = 53 to 56) or PncOMPC (n = 44 to 53), or a control vaccine (n = 40 to 47).

Tables

  • Figures
  • TABLE 1.

    GMCs of serum IgG antibodies to pneumococcal capsular PSs in infants immunized with a 7-valent pneumococcal conjugate vaccine or control vaccine at 2, 4, and 6 months of age and boosted with a homologous vaccine at 12 months of age

    SerotypeVaccineGMC [μg/ml (95% CI)] in infants at age (mo):
    2 (n = 52-58)7 (n = 53-55)12 (n = 52-56)13 (n = 46-55)24 (n = 44-54)
    4PncCRM0.12 (0.09-0.17)1.71 (1.32-2.20)0.42 (0.34-0.53)2.55 (1.99-3.27)0.50 (0.40-0.62)
    PncOMPC0.17 (0.13-0.24)2.74 (1.92-3.91)1.12 (0.85-1.48)4.63 (3.09-6.95)1.11 (0.85-1.45)
    Control0.10 (0.08-0.14)0.05 (0.04-0.07)0.09 (0.07-0.12)0.11 (0.08-0.14)0.19 (0.15-0.25)
    6BPncCRM0.21 (0.15-0.30)1.99 (1.35-2.95)0.92 (0.64-1.32)9.02 (6.48-12.54)1.48 (1.11-1.99)
    PncOMPC0.26 (0.18-0.36)0.40 (0.29-0.54)0.50 (0.37-0.67)1.76 (1.15-2.67)0.95 (0.65-1.39)
    Control0.16 (0.11-0.22)0.09 (0.07-0.12)0.13 (0.10-0.18)0.15 (0.12-0.20)0.25 (0.19-0.32)
    9VPncCRM0.26 (0.19-0.35)2.47 (1.97-3.11)0.81 (0.66-1.00)3.97 (3.20-4.91)0.87 (0.67-1.12)
    PncOMPC0.24 (0.18-0.33)1.98 (1.55-2.54)1.03 (0.8-1.33)4.05 (3.14-5.22)1.21 (0.87-1.69)
    Control0.20 (0.15-0.27)0.10 (0.07-0.13)0.17 (0.13-0.23)0.21 (0.16-0.27)0.33 (0.25-0.45)
    14PncCRM0.28 (0.19-0.41)6.26 (4.77-8.20)2.63 (2.12-3.26)10.80 (8.29-14.06)1.86 (1.47-2.36)
    PncOMPC0.38 (0.26-0.56)2.96 (2.05-4.25)1.25 (0.93-1.68)5.31 (3.68-7.66)1.50 (1.06-2.13)
    Control0.46 (0.31-0.68)0.21 (0.16-0.27)0.19 (0.15-0.24)0.21 (0.17-0.27)0.28 (0.21-0.37)
    18CPncCRM0.16 (0.11-0.23)3.55 (2.80-4.49)0.88 (0.73-1.07)6.51 (5.04-8.42)0.99 (0.77-1.28)
    PncOMPC0.21 (0.15-0.30)1.03 (0.76-1.40)0.56 (0.44-0.72)3.06 (2.27-4.12)0.70 (0.51-0.97)
    Control0.24 (0.16-0.34)0.08 (0.06-0.11)0.09 (0.07-0.11)0.10 (0.08-0.13)0.20 (0.13-0.29)
    19FPncCRM0.42 (0.30-0.60)3.28 (2.56-4.20)0.86 (0.65-1.13)4.96 (3.86-6.36)2.14 (1.47-3.12)
    PncOMPC0.54 (0.39-0.75)3.54 (2.74-4.57)2.37 (1.65-3.40)8.58 (6.10-12.08)4.80 (2.95-7.82)
    Control0.37 (0.26-0.52)0.22 (0.17-0.29)0.34 (0.24-0.46)0.40 (0.31-0.53)0.62 (0.47-0.82)
    23FPncCRM0.19 (0.13-0.28)2.51 (1.84-3.43)0.79 (0.59-1.05)6.20 (4.51-8.52)1.28 (0.98-1.68)
    PncOMPC0.32 (0.23-0.45)0.62 (0.46-0.82)0.64 (0.47-0.86)2.14 (1.54-2.99)1.05 (0.76-1.44)
    Control0.18 (0.13-0.25)0.10 (0.07-0.12)0.13 (0.10-0.18)0.15 (0.12-0.20)0.23 (0.17-0.31)
PreviousNext
Back to top
Download PDF
Citation Tools
Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
Nina Ekström, Heidi Åhman, Jouko Verho, Jukka Jokinen, Merja Väkeväinen, Terhi Kilpi, Helena Käyhty the Finnish Otitis Media Study Group
Infection and Immunity Dec 2004, 73 (1) 369-377; DOI: 10.1128/IAI.73.1.369-377.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
Nina Ekström, Heidi Åhman, Jouko Verho, Jukka Jokinen, Merja Väkeväinen, Terhi Kilpi, Helena Käyhty the Finnish Otitis Media Study Group
Infection and Immunity Dec 2004, 73 (1) 369-377; DOI: 10.1128/IAI.73.1.369-377.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Bacterial
Antibody Affinity
Meningococcal Vaccines
otitis media
Pneumococcal Vaccines

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522